by Karen O'Hanlon Cohrt | Sep 24, 2023 | Disease Models
In our last few liver articles, we highlighted the urgent need for new models and treatments for non-alcoholic steatohepatitis (NASH), and looked at the potential for human liver organoids to not only model disease, but also to test new drugs for safety and efficacy....
by Karen O'Hanlon Cohrt | Jul 18, 2023 | Disease Models
The lack of approved treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatosis (NASH) is largely explained by the shortcomings of cellular models used to unravel disease mechanisms, identify and validate new drug targets, and screen...
by Karen O'Hanlon Cohrt | Apr 4, 2023 | Disease Models
Welcome to our new mini-series about liver organoids. In Part 1, we focus on non-alcoholic steatohepatitis (NASH), a severe and prevalent form of non-alcoholic fatty liver disease for which no drugs have been approved. We look at the current treatment landscape for...
by Karen O'Hanlon Cohrt | Feb 19, 2023 | Trends
Welcome to Part 4 of our series about the blood brain barrier (BBB)! Here, we highlight the rising global burden of neurological disorders, and recap on the challenges surrounding drug safety and toxicity in relation to the BBB. As industry speeds ahead with novel...
by Karen O'Hanlon Cohrt | Jan 26, 2023 | Trends
Welcome to Part 3 of our blog series covering the blood brain barrier (BBB). In Part 1, we looked briefly at how the BBB was discovered and presented what we currently know about its composition and functions. Part 2 focused on the need for reliable BBB models in drug...
